UOE/2015/042 Provision of over-encapsulated Sitagliptin (Januvia), Pioglitazone (Actos) and Cangliflozin(Invokana) for double-blind randomised/clin trials.
What the buyer wrote
The University of Exeter is advertising a Call for Competition in seeking a suitable and capable provider ofinvestigational medicinal product for use by its Medical School as part of a diabetes clinical trial. The Universityof Exeter Medical School is undertaking a MRC-funded study aiming to develop a stratified approach in Type2 diabetes that will result in more effective use of glucose lowering therapy. The Trimaster trial, sponsored bythe Royal Devon ανδ Exeter NHS Foundation Trust (RD&E FT) is a randomised double-blind Cross-Over trial ofthree standard diabetes therapies, a DPP4 inhibitor, SGLT2 inhibitor and thiazolidinedione as third line therapyin 600 patients with type 2 diabetes. It…
Bid for this and lost? There is a short window in which the decision can be questioned.
Awarded to
Details
- What the buyer calls it
- UOE/2015/042 Provision of over-encapsulated Sitagliptin (Januvia), Pioglitazone (Actos) and Cangliflozin(Invokana) for double-blind randomised/clin trials.
- How they are buying
- Advertised, open to anyoneAny supplier could bid without being invited first.
- Type
- goods
- Work starts
- 27 Sep 2015
- Work ends
- 1 Jul 2019
Who the buyer named
IT Category Manager was the named contact on this notice.